



Meaningful Advancements in Health Equity

2024 Annual Report



www.themaxfoundation.org



Table of Contents

03	Letter from CEO & Board Chair
05	2024 Global Impact
09	Treat
11	Amplify
13	Sustain
15	Financials
16	Donors & Supporters

Our Mission



Our mission is to accelerate health equity.

We do this by delivering medication, technology, and services to patients facing cancer and other critical illnesses, focusing our energy on those whom no one else is helping.

Our Vision

A world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and hope.

Letter from CEO & Board Chair

Three years back, we launched our ambitious five-year Equity in Action strategic plan, an unwavering commitment to accelerating global health equity focused on helping people and creating quantifiable impact. It ensures that every action we take is purposeful and transformative for those who need it most – patients, communities, and healthcare systems in the world’s most critically underserved regions. We are happy to report that 2024 was a year of continued progress along all three measures that we set for ourselves, tracking at or above our goals.

Notably, we made substantial advances in expanding access to life-extending treatments. Through our newly launched programs, we provided treatment and care to nearly 300 women with advanced breast cancer and 200 individuals diagnosed with

chronic lymphocytic leukemia. Thanks to the commitment of our extraordinary partners worldwide – who share our belief that access to medicine is a fundamental human right – we were able to scale these initiatives up rapidly, delivering meaningful impact to those in need.

A cornerstone of our strategic plan, our patient outreach expanded significantly in 2024. We enrolled more than 4,200 new patients and reached a total of nearly 40,000 patients worldwide through at least one of our programs. Our global reach grew to 84 countries. With a portfolio of 15 breakthrough therapies, we are now addressing 14 critical diseases. Ninety percent of patients in our programs remained enrolled year-over-year, underscoring our commitment to care continuity.

In 2024, I traveled to Nepal and met Rajkumar Thapar, Chief Pharmacist of Patan Hospital in Kathmandu, among others. Seeing the duty of care with which he oversaw the storage and dispensation of the medication we provided was both a proud and sobering moment. Standing there in Patan Hospital, I saw both progress and the urgent need for more, a powerful reminder that for every patient whose voice we amplify, many more are still waiting for the opportunity to receive the treatment and care they deserve.

From our beginnings as a small group of dedicated volunteers in 1997 helping Latin American families access education and support for children with leukemia, The Max Foundation has grown into a vibrant team of 92 passionate individuals, with

presence in 24 countries and speaking 45 languages – driven by a single-minded mission to ensuring that geography should not determine destiny.

As we look at the milestones of 2024, we are humbled and endlessly inspired by the spirit of our global team members, the resilience of our patients, the dedication of our partners, and the unwavering commitment of our supporters. Together, united by our humanity, we know we can succeed in our pursuit of a world where everyone can strive for health with dignity and hope.

Pat Garcia-Gonzalez, *CEO and Co-Founder*
Curt Malloy, *Board Chair*



“ Patient Perspective

Sometimes I don't have money, but the transport money helps me so much. Asante sana. (thank you).

Penina from Nairobi

Penina, a woman living with breast cancer from Nairobi, Kenya, faced significant challenges beyond medical care. Something as simple as transportation was a daunting hurdle, as financial constraints can make a journey to the hospital feel impossible. Max's Last Mile program provides transportation vouchers, ensuring that patients like Penina can reach their appointments without the added burden of travel costs.



2024
Global Impact

Accelerating health equity with sustainable outcomes for patients, health systems, and communities in low- and middle-income countries

39,271

Patients with cancer and critical diseases received access to treatment and/or support services

50%

More than 50% of patients were provided with treatment and accompaniment services, driving sustainable outcomes

4,240

4,240 newly enrolled patients received treatment for the first time

108

Clinical training for 108 healthcare professionals across 25 countries helped strengthen healthcare system capacity, enhancing medical expertise and quality of care

165

165 biopsy instruments provided to partner institutions in three resource-limited countries, enhancing breast cancer diagnosis and care

101%

All six Social Determinants of Health programs increased in patient reach, by a combined total of 101% with 11,433 patients supported

15

15 therapies for 14 critical diseases delivered, increasing the number of disease areas supported

84

Our access programs covered 84 countries, 22 receiving a new treatment for the first time

10M

Nearly 10M daily doses of breakthrough cancer and rare disease medication delivered

\$358M

\$358.6M in estimated value of the strategic investment in medicines enabled 37,248 patients across 79 countries to receive treatments, advancing global health equity

9,936

In 2024, we provided a total of 9,936 diagnostic tests and tools to patients across 38 countries.

17

17 site capacity assessments conducted—an important measure of a country's health system readiness and resilience to diagnose and treat cancer

9


9 Corporate partners in our Humanitarian Partnership for Access to Critical Treatments (Humanitarian PACT), enhancing our ability to provide medicines and diagnostics

Meaningful Advancements

in Health Equity

We provided access to treatment to nearly 300 women with advanced breast cancer—a disease responsible for over 55% of deaths in low- and middle-income countries.

200 patients diagnosed with chronic lymphocytic leukemia received treatment as part of our newly launched CLL program.



Treatment for paroxysmal nocturnal hemoglobinuria (PNH) will become available in more than 50 resource-challenged countries. PNH is a rare and debilitating genetic blood disorder that, if left untreated, can progress into life-threatening complications.

Reflecting our strong belief that equitable access to care depends on strong partnerships, we collaborated with a total of 938 partners, including 9 new treating institutions and 28 new partner physicians.

In 2024, we expanded access to 15 treatments across 14 diseases. We added a new therapy for individuals with advanced breast cancer, and launched a third-line treatment option for CML patients. These developments mark significant progress in closing treatment gaps for patients in need.

To support our partner physicians in using innovative medicines to treat breast cancer and CLL, we collaborated with our professional partners to provide specialized training for 108 healthcare professionals across 25 countries, enhancing their ability to care for patients.

True to our mission of delivering integrated patient care and removing barriers to treatment, we provided vital support to 11,000 patients—including transportation grants, educational assistance, and disease awareness programs to help them navigate their healthcare journey.



Our global geographic reach increased to 84 countries with the opening of patient treatment and support programs in three new countries for the first time, Eswatini, Gambia, and Burundi.

Max Think Tank, our thought leadership initiative uniting key partners, supporters, patient advocates, and Max team members, was launched to drive actionable solutions for patients in urgent need of treatment. It provides a collaborative forum to tackle strategic challenges, share insights, and devise strategies to overcome real-world barriers. The engagements have already sparked practical recommendations for expanding diagnostics, enhancing quality assurance, and strengthening healthcare training in low- to middle-income countries.

Treat More Patients

Progress on our Priorities

In 2024, we made significant strides in advancing health equity in some of the world’s most underserved communities. We increased the number of patients receiving treatment, expanded training for healthcare professionals, and improved access to diagnostics. In doing so, we advanced the resilience and long-term sustainability of in-country healthcare systems—with the goal of better equipping them to serve their communities now and in the future.

Our access programs and accompaniment services reached nearly 40,000 patients with cancer and critical diseases, more than 4,200 of whom were newly enrolled and receiving treatment for the first time (Figure 1). Over 20,000 patients were also provided with essential, accompanying services free of cost, including transportation assistance, schooling support, and disease awareness education, proven to be health barriers in low-resource countries.

We expanded our programs in advanced breast cancer and chronic lymphocytic leukemia (CLL). Launched in 2023, the programs covered nearly 300 breast

cancer patients and 200 CLL patients this past year.

Our global geographic reach increased to 84 countries with the opening of patient treatment and support programs in three new countries, Eswatini, Gambia and Burundi. With the introduction of a new therapy for advanced breast cancer, and a third line treatment option for chronic myeloid leukemia, our portfolio grew to cover 15 therapies for 14 critical disease states.

The severe shortage of diagnostic tools in parts of the world delays detection and limits treatment options, putting lives at risk. In 2024, we expanded diagnostic capabilities for breast cancer, delivering 165 biopsy instruments. We provided a total of 9,936 diagnostic tests to patients across 38 countries, enabling our physician partners to better monitor their patients response to therapy. In countries where there are no diagnostic tests available for a rare form of leukemia, in collaboration with our partners at Fred Hutch, we provided 220 Spot On CML tests to low- and middle-income countries, bringing critical testing within reach for more patients.



“ Patient Perspective

I could never have afforded these medicines on my own. I am immensely grateful to The Max Foundation for providing the medicine and covering my travel expenses and giving me another chance in life.

Radhika from Nepal



Radhika was diagnosed with breast cancer in 2020. Her request to her doctor was simply to give her five more years to support her elderly parents and teenage daughter. Today, she is back at work and raising her daughter. With the support of our Last Mile program, she’s able to access essential medicines and additionally cover her travel expenses for hospital visits, allowing her to focus on her health and family.




Figure 1: Number of patients who accessed treatment through Max Access Solutions from 2020-2024, globally

Amplify Our Voice

Progress on our Priorities

For patients living with critical illnesses, having a voice is more than just communication – it is empowerment, allowing them to share their unique experiences and gain from shared insights. This engagement can significantly influence their health outcomes and quality of care. In communities where healthcare disparities run deep and socioeconomic factors play substantial roles, patients and families lack this agency. Recognizing this reality, one of our strategic goals is to ensure that their challenges, experiences, and humanity are amplified and acted upon.

In 2024, we enhanced our global presence externally by expanding speaking engagements, leading sessions, and actively participating in key international conferences alongside esteemed peers, industry leaders, and dedicated advocates. We focused on the fields of cancer research, treatment, patient care, and support. We deepened and broadened strategic partnerships, extended our networks, and refined our Max Think Tank thought leadership platform—transforming it into a dynamic two-way forum for education, awareness, and actionable innovation.



Internally, our global team grew by 10 members, bringing our total workforce to 92 across 24 countries. With 45 languages spoken among team members who directly engage with patients, we are well equipped to serve diverse communities worldwide. This strategic expansion strengthened our online presence as well, amplifying inspiring patient stories, highlighting local healthcare challenges, and sharing valuable insights from medical professionals. Additionally, we transformed our website into a dynamic and engaging platform—designed to educate, inform, and inspire—reinforcing our urgent commitment to accelerating health equity.

In celebration of Women's Equality Day 2024, our CEO, Pat Garcia-Gonzalez, was recognized as one of the 100 most influential women in Oncology to follow on social media. The Max Foundation's commitment to health equity was highlighted in the ASCO Post through an in-depth interview with Pat. As a key player in the Access to Oncology Medicines (ATOM) Coalition, we continue to advocate for humanitarian access to cancer treatments, with Pat serving as a member of the executive committee.



Partner Perspective

Our goal is to enhance patient care and outcomes on a global scale. This mission is best achieved through collaboration with diverse professional organizations. After a 20-year delay, specific treatments for PNH are finally becoming accessible to patients in low-resource countries. We extend our heartfelt gratitude to The Max Foundation for their tireless efforts in making this achievement possible. IPIG is proud to support this initiative by contributing to the education and training of healthcare professionals in these underserved regions.

Antonio Risitano, MD, PhD
International PNH Interest Group (IPIG) President and Chair



Scan to read article

Included in the 40 presentations and six abstracts presented by The Max Foundation to external audiences in 2024, was a peer-reviewed manuscript, "Treatment Access for Gastrointestinal Stromal Tumor in Predominantly Low- and Middle-Income Countries (LMICs)," published in JAMA Network Open. An important finding of the publication is highlighted in this quote: "These findings suggest that patients with GIST who were predominantly from LMICs and received orally administered therapy through a large global access program had clinical outcomes similar to those observed in patients treated in high-resource countries."

Sustain Our Work Through Robust Partnerships



Progress on our Priorities

“Partnerships are crucial for nonprofit healthcare organizations to achieve health equity,” says the World Health Organization. A foundational pillar of our five-year Equity in Action strategic plan is to sustain and advance our work through robust partnerships – critical if we are to reach people in low- or middle-income countries and ultimately promote a more equitable system for all. To that end, collaborations and partnerships formed the cornerstones of 2024. Our distribution of nearly 10 million daily doses of high-impact medicines to 84 countries, supporting the treatment of 14 critical diseases, was made possible through diverse partnerships with the Humanitarian Partnership for Critical Treatments (Humanitarian PACT). This robust coalition of individuals and organization committed to improving health equity includes physicians, treating institutions, NGOs, Ministries of Health, and Corporate partners (Figure 2).

We expanded our collaboration with Novartis to include treatment access for paroxysmal nocturnal hemoglobinuria (PNH), a rare and potentially life-threatening disorder. Starting in 2025, for the first time, patients in more than 50 countries will begin to have access

to a viable treatment option, marking a significant step forward in global healthcare equity. Additionally, we proudly welcomed the International PNH Interest Group (IPIG) into the Humanitarian PACT. With their deep expertise in patient care and disease management, IPIG will play a crucial role in improving outcomes for individuals with PNH, in these resource-limited regions. Thanks to our valued partner, global medical technology company, BD (Becton, Dickinson and Company), we expanded diagnostic access by delivering 165 biopsy instruments at no cost to low- and middle-income countries, a severely limited resource and major barrier to effective treatment. More women can now receive much needed and accurate diagnoses in a timely manner.

Through our collaborative Max Think Tank forum—bringing together individual supporters, patient advocates, and Max team members—we are developing actionable recommendations to expand diagnostics, enhance quality assurance, and strengthen professional training. These efforts are essential to fortifying in-country healthcare systems and ensuring sustainable improvements in patient care.



Partner Perspective

This initiative is aimed to bring critical care closer to patients diagnosed with chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).

Kenyan Ministry of Health




Figure 2: Number of professional affiliations

For over 20 years, the Max Foundation has operated a CML access program in Kenya. In 2021, a public-private partnership between the Max Foundation and the Kenyan Ministry of Health took over national governance, with distribution managed by the Kenya Medical and Supplies Agency (KEMSA). The program expanded to create a decentralized approach, from a single private hospital in Nairobi to four public hospitals, transferring 200 patients and enrolling over 100 new ones. In 2024, it expanded to include breast cancer medication, enhancing clinical outcomes.

This decentralized approach allows patients to receive treatment at regional and county levels, making it more accessible and reducing the need for long-distance travel, a significant issue in resource-challenged countries.

Revenue & Expenses

As of December 31, 2024

Revenue		
In-kind pharmaceutical contributions*	\$	297,848,824
Contributions, grants, & sponsorships	\$	11,982,570
Diagnostic program revenue	\$	252,881
Other income	\$	68,389
Total	\$	310,152,666
Expenses		
Program expenses	\$	9,402,220
Program in-kind expenses	\$	358,850,694
Management & general expenses	\$	2,484,550
Fundraising expenses	\$	886,668
Total	\$	371,624,132

**The Organization recognizes in-kind contributions consisting of pharmaceuticals, medical devices, and related products. These goods are recorded as inventory and revenue at fair value at the time received and as a reduction to inventory and program expense when the goods are distributed. Pharmaceutical inventory is released using a specific identification method based on expiration date and is reviewed at least annually for impairment. Pharmaceutical inventory is disposed and written off as obsolete when it is determined the pharmaceutical cannot be imported into a specific country of destination with shelf-life sufficient to comply with local importation regulations and the Organization's own guidelines.*

Donors & Supporters



Humanitarian PACT Members & Supporters

- ABC Global Alliance

American Society for Clinical Pathology

BeOne Medicines USA *

BD (Becton, Dickinson and Company)

Bristol Myers Squibb *

Cepheid *
- Eli Lilly and Company

Incyte Biosciences International Sàrl *

International Workshop on CLL (iwCLL)

International PNH Interest Group (IPIG)

Novartis *

Pioneer in Treatment Access

Pfizer Inc. *

Takeda Pharmaceuticals International *

Donors

- Aimee Anselmo

Alan D. Smith

Amadou Diarra, PhD

Amanda & Josh Sandoz

Andrea Sparrey & Amit Kapur

Andy & JoAnn Stergachis

Andy Peet

Ann Houseman

Anonymous (18)

Anthony Rizzuto

Aparna Anderson, PhD

Arlene Saryan & Christian Alexander

Armenian Missionary Association of America *

Ashish Mahajan

Avedisian 575 Foundation *

Azadeh Joharifard

BD (Becton, Dickinson and Company) *

Benjamin & Tinya Anderson

BeOne Care Foundation *

BeOne Medicines USA *

Beverly Mitchell, MD

Brian Meenaghan *

Bristol Myers Squibb *

Bryan Murphy-Eustis *

Cari & Greg Benn *

Carlos Rodriguez-Galindo, MD

Carmen Merino

Caroline Hoang

Carolyn Hubbard

Cecilia Yeung
- Cepheid *

Chris Korsmo

Chris Pierce & Jon Pollock

Cristin & Andrew Gordon-Maclean

Comenat Family

Curt & Ana Malloy

Dallas Smith

Dan Milner

David Palacios

DKI Health

Dimple Sahay

Douglas Ellenoff & Sabrina Allan

Garo Armen, Ph.D

Edgar & Carrie Thomas

Edus & Linda Warren

Eli Lilly and Company *

Ellen Baker

Emily & Eric Johnson

Erin Schwartz & Eric Ozretich

Evlyn & John Schmidt

Fatima Scipione

Fausto Loberiza

Fred Hutch Cancer Center *

Frederick Canby

Gates Foundation *

Geoffrey Cook

George Svokos

Giancarlo Francese & Ismael Kossih

Gina Noh

Glen Weissman & Cherie Rumbawa

Graciela Mabel Woloj Rothstein, PhD *
- GRAIL, Inc. *

Greg and Angie Schroeder

Gregory Kalemkerian & Mary Varterasian

Incyte Biosciences International Sàrl*

Irine Datikashvili-David ◇

Irv Weissman, MD & Ann Tsukamoto-Weissman, MD *

James Daly

Janssen Pharmaceuticals / Johnson & Johnson *

Jayasree Iyer

Jeff Bogosian

Jerald Radich, MD & Dorcas Dobie

Jerry P. Scott, CPA & Odette Batik

John & Karen Menapace

Joseph Ward

Joyce Hanson

Julia Lee

Julia Perkins

Julie Jenson

Karen Dindial

Karen M. Kasprzyk

Kelly & Jim McKay

Kenneth Kieffer ◇

Klaus Rennack ◇

Larry & Amy Corey

Laura Cisar & Robert Gowin

Lawrence N Shulman, MD

Lindsay & David Kurs

Lisa Bellucci

Liz Dwyer

Donors, continued

Lynn McRoy
Manan Shah
Manoj Menon
Maria Fasulo & Laurie Olson
Maria Pia Ruffilli, MD & Susan Silberman *
Mariam Izoria ♦
Mario Borain ♦
Mark & Joan Murray
Martina Schroetter
Mary Kay Haggard
Matt & Carly Coleman
MC Ong
Melissa Gunn
Mentha Benek
Michael Mandola
Micki Trager
Mike & Sarah Hamilton
Nana Rusishvili ♦
Nancy Grande
Neal Parry & Shannon Hieger ♦
Nerissa Teichroew & Mike Young
Novartis Pharmaceuticals Corporation *
Occidental Lodge #72 F. & A.M. *
Oluyemi Ajayi
Orin Levine & Amie Batson
Pamela Baity
Pat Garcia-Gonzalez * ♦
Patricia Keegan *
Patricia Pearce
Paul Aliu, PharmD
Paula & Paul Boulton *
Pfizer Inc *
Rakesh R Bansal
Richard Adrouny

Rob Keel & Anna Paola Pradal *
Rob Ziemak
Robert Hershberg *
Robin Taylor
Roche Global / Genentech *
Ron Kurtz
Rosanne Rotondo * ♦
Sara Billington
Sarah Cornhill
Sarah Reed
Shelly & Jonathan Karuna
Siew Gim Lee
Sonia Snell
Stephen & Andrea Scalia *
Steve Price & Marian Vazquez
Susan & Bob Kressek
JACE Foundation *
Sylvia Angel
Tabatha Light
Takeda Pharmaceuticals International *
Tang Thi Thanh Thao
Tanner Pharma Group *
Tara Berringer
Teresa Rafferty
Teri Tanimura
Terri-Ann Betancourt *
Tiffany Patrick *
Timothy Dorsey
Toni Hoover & Alfred Nettles
Tracey Higgins
Valerie Bressler-Hill
Vaughn Edelson ♦
Walter Otieno Mwanda
We Work For Health *
William & Elizabeth Wrigglesworth

This list includes people and corporations who gave \$250 or more in 2024. All donations, big and small, help us reach more patients in need. Thank you to everyone who contributed to the mission of The Max Foundation.

** Visionary Council: Corporate and individual donors who have made a significant contribution to our organization. True to the definition of a visionary, these donors have a strong vision of the future and have taken it upon themselves to contribute so The Max Foundation can make larger strides toward accelerating health equity.*

♦ Champions Circle: A group of generous monthly global givers helping us accelerate health equity every day, year-round.

Leadership Team

Bryan Murphy-Eustis
Vice President, Program Strategy & Partnerships

Catherina Scheepers
Region Head for Africa

Geoff Cook
Vice President, Communications & Development

Inés García González
Region Head for Latin America

J. Michael Wrigglesworth
Vice President, Program Operations

Pat Garcia-Gonzalez
Chief Executive Officer

Mei Ching Ong
Region Head for Asia & Eastern Europe

Board of Directors

Amadou Diarra, PhD
Board Member; Former Senior Vice President of Global Policy, Advocacy, and Government Affairs at Bristol Myers Squibb

Aparna Anderson, PhD
Board Member; Portfolio Statistics Leader at the Gates Medical Research Institute; Member of the American Statistical Association

Curt Malloy, JD, MPH
Board Chair; Senior Vice President, Strategic Operations at HDT.bio

Harout Semerjian
Treasurer of the Board; former CEO and President of GlycoMimetics, Inc.

Jerald Radich, MD
Board Member; Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center

Graciela Mabel Woloj Rothstein, PhD
Board Member; Principal at MW Consulting

Maria Pia Ruffilli, MD
Board Member; Retired (former Senior Director, International Public Affairs, Therapeutic Area Team, Team Leader - Pfizer)

Pat Garcia-Gonzalez
Chief Executive Officer

Paula Boulton
Board Member; Principal at PTB Consulting LLC

Robert Farmer
Honorary Board Member

Susan Jerian, MD
Board Member; President and Founder, ONCORD, Inc.

Viji Venkatesh
Board Member; Former Region Head of The Max Foundation for India & South Asia

Think Tank Advisors

Alan D. Smith
Alexandru Eniu, MD, PhD
Alison Roos, PhD
Amanda Schwartz
Anna Schuh
Arun Shahi, MD
Avinash Kumar Singh, MD, DM
Beverly Mitchell MD
Carlo Nalin, PhD
Chirag A Shah, MD
Chris Korsmo
Dan Milner, MD
David Essayan, MD
Deepak Bansal, MD
Deron Reid, MD
Devinder Singh Sandhu, MD, DM
Edward Cliff, MBBS, MPH
Eunice Orekha
Fatima Cardoso, MD
Fatima Scipione
Fisihatsion Tadesse, MD
Handel Roger Emery, MD, FRCP
Hari Suma Menon, MD, DM
Harout Semerjian
Hemant Malhotra, MD

HH Princess Dina Mired
Isabelle Lindenmayer
Jebasingh Joseph, MD, DM
Jeff Lane, JD, MPH
Julie Jenson
Karen Meliksetyan, MD
Kari Edwards, PhD
Lawrence N Shulman, MD
Maia Thrift-Perry, MA, MPH
Manan Shah
Manoj P Menon, MD
Michael Mandola
Narine Ghazaryan, PhD
Natanya M. Candelario, PharmD, MS
Nelson de Franco
Nirmesh Prakash
Oliver Henke, MD, M.Sc, PhD
Patricia Silva, MD
Paul Aliu, PharmD, MRPharmS
Pramod John George
Prof. Irine Datikashvili-David
Rajeev Gupta, DNB
Rebecca Begley, PhD
Rod Padua
Rosanne Rotondo

Runcie C.W. Chidebe, Dip., MSc
Sam Ellis
Staci J Kearney, PhD
Steven Jones
Sugeeth M Thambi, MD
Temidayo Fadelu, MD, MPH
Tiffany S Patrick
Vasile Musteata, MD

Global Team

Africa & Middle East

Aicha Betty Sow
Ayanda Ntombela
Catherina Scheepers
Elsy Onoya
Eunice Mwimba
Evan Mapelu
Geraldine Botha
Jean Claude Mutabazi
Jubril Esan
Kayinfa Nicole
Lucy Mwangi
Mario Borain
Maxane Kilosho
Meron Hiruy
Mmamolahlegi Mahopo
Nicole Jordaan
Perpertual Asiamah
Tayamika Zalinga Phiri
Tenaye Ashebir
Tresor Mbuyi
Vimbai Taruwedzera

Asia & Eastern Europe

Chanikan Wongsamai
Mariam Izoria
Mei Ching Ong
Munkhzul Milkhaabaatar
Natia Kakutia
Nelia Medina
Nor Aina Abd Rahim
Nur Fatiha Nabila Mohd Nor
Nur Ikilil Rifhan Jalil
Nur Izzati Mohd Rodzi
Sabina Ghale
Saif Arman Shah Mohamad
Shalini Subramanian
Socheatha Jim
Sukhrob Saliev
Sweta Agrawal
Thao Tang Thi Thanh
Wirat Sae-Kuai

Latin America

Cristian Neves
Cynthia Figueroa Guerra
Inés Garcia González
Ivagna Rondón
Jacqueline Montúfar
Karen Chur
Lyat Granati
María Julia Sánchez
Mariana Rubi Gonzalez
Martha Rosario Molina
Melisa Fazio
Verónica Ayala
Victoria Duhalde

Headquarters

Alexander Laya Martinez
Alicia Annamalay
Andrielle Yost
Angel Kaushish
Anshika Tandon
Baily Hays
Bryan Murphy-Eustis
Charmaine Vazquez
Colin Forsyth
Craig Anderson
David Palacios
Diane Cryder
Emanuela Chiaranda
Emily Muirhead
Emily Vega
Emma Kgopa-Chabangu
Geoffrey Cook
James Wrigglesworth
Jennifer Rynning
Justin Craig
Kelsey Bray
Laura Mapp
Lisa Walters
Lissa Kendall
Mahmoud Alballah
Marine Durand

Mercedes Arteaga
Nicholas Schmidt
Pat Garcia-Gonzalez
Patrick Flanagan
Pooja Patil
Rachel McKelvey
Soon Beng Yeap
Sudha Samineni
Tomara Henderson

South Asia

Ashika Naik
Ashok Boricha
Beena Narayanan
Jyotiy Parameshwaran
Komal Surve
Phillip Fernandes
Prasad Kothekar
Priyanka Kandalgaokar
Santosh Kadam
Shaileja Nambiar
Shalini Subramanian
Shrutika Kaspale
Steven Mathew
Urvashi Negi

Partner Nonprofits

Bolivia

Fundación Esperanza Nueva
Celebrando la Vida

Benin

Claudine Talon Foundation

Chile

CONAC

Ecuador

Esperanza y Vida

Ethiopia

Ethiopia CML Patients Association

Guatemala

ASOPALEU

India

Friends of Max

Kenya

Henzo Kenya

Nigeria

MaxCare Nigeria

Paraguay

FUNCA

Peru

Esperantra

Philippines

Touched by Max

Malaysia

Max Family Society Malaysia

US / Global

Fred Hutchinson Cancer Research Center
Partners in Health
Union for International Cancer Control
Washington Global Health Alliance

Zimbabwe

CML Zimbabwe Trust

Partner Healthcare Institutions

Argentina

Academia Nacional de Medicina
FUNDALEU
Hospital Centenario
Hospital Central
Hospital Nacional de Clínicas
Hospital Posadas
Hospital Ramos Mejía
Hospital Rossi
Hospital San Martín
Private Office Dr. Bibiana Espina
Private Office Dr. Javier Bordone
Private Office Dr. Ricardo Aguirre
Private Office Dr. Victoria Welsh
Private Office Dr. Virginia Guerrero

Armenia

Yeolyan Hematology and Oncology Center

Azerbaijan

National Hematology and Transfusiology Center

Bahamas

Hematology Oncology Consultants

Belarus

Minsk Scientific and Practical Center of Surgery,
Transplantology and Hematology

Benin

Centre National Hospitalier Universitaire – Hubert K. MAGA

Bhutan

Jigme Dorji Wangchuck National Referral Hospital

Bolivia

Clínica Los Olivos
Global Laboratorios
Hospital de Clínicas Universitario
Instituto Boliviano de Oncohematología
Instituto Oncologico del Oriente Boliviano
Private Office Ricardo Villegas

Brazil

Centro de Hematologia e Hemoterapia – Universidade

Burkina Faso

Centre Hospitalier Universitaire Yalgado Ouedraogo

Cambodia

Hebron Medical Center
Mercy Medical Center Cambodia

Cameroon

Hopital General Yaoundé

Central Africa Republic

Service d'hématologie du Centre National de Transfusion
Sanguine

Chile
Clínica Icos
Clínica Las Condes
Clínica Reñaca
Fundación Arturo López Pérez
Hospital Barros Luco
Hospital Base Puerto Montt
Hospital Clínico Universidad Católica
Hospital del Salvador
Hospital Dr. Hernán Henríquez Aravena
Hospital JJ Aguirre
Hospital La Serena
Hospital Naval
Hospital Regional de Antofagasta
Hospital Regional de Concepción
Hospital Regional de Talca
Hospital Regional de Temuco
Hospital Regional de Valdivia
Hospital Roberto del Río
Hospital San Borja Arriarán
Hospital San Juan de Dios
Hospital Sótero del Río
Hospital Van Buren
INCAN
Private Office Dr. Javier Anabalón

Cote d’Ivoire
CHU de Yopougon

Democratic Republic of Congo
Centre Hospitalier Nganda

Dominican Republic
Hospital Heriberto Pieter

East Timor
Bairo Pite Clinic Lanud

Ecuador
Hospital Metropolitano
SOLCA Núcleo de Quito

El Salvador
Hospital Nacional Rosales

Eswatini
Manzini Government Hospital

Ethiopia
Tikur Anbessa (Black Lion) Hospital

Fiji
Colonial War Memorial Hospital

Gabon
Institut de Cancerologie Angondje

Gambia
Edward Francis Small Teaching Hospital

Georgia
LTD M. Zodelava Clinic
Medinvest-Institute of Hematology and Transfusiology

Ghana
Komfo Anokye Teaching Hospital
Korle-Bu Teaching Hospital

Guatemala
Hospital General San Juan de Dios
Hospital Roosevelt

Guinea
CHU Ignace Deen Conakry/Guinee

Haiti
Zanmi Lasante

Honduras
Centro de Cancer Emma R. De Callejas

India
Ananta Medical College and Research Centre
Mahavir Cancer Sansthan
A.M.R.I Hospital
Aagam Cancer Centre
Acharya Tulsi Regional Cancer Treatment and Research
Action Cancer Hospital
Advanced Centre for Treatment, Research and Education in Cancer
AIIMS Bhubaneswar
Alexis Hospital
All India Institute of medical Science
All India Institute Of Medical Science (AIIMS)
Amala Hospital
Amrita Institute of Medical Sciences
Antia’s Clinical & Haematology Lab
Apex Wellness Hospital
Apollo Cancer Institute (Duplicate)
Apollo Cancer Institutes
Apollo Hospital (Navi Mumbai)
Apollo Hospitals (Hyderabad)
Apollo Hospitals, Madurai
Apollo Multispecialty Hospital
Apollo Specialty Hospitals (Chennai)
Arogya Multi-Speciality Clinic
Arunodaya Medical Centre
Asirvatham Super Speciality Hospital

Aster Medcity Hospital
Aster MIMS Hospital
Ayush Haemato-Onco Clinic
B. L. Kapoor Super Speciality Hospital
Batra Hospital and Medical Research Center
Bhagwan Mahaveer Cancer Hospital & Research Centre
Bhaktivedanta Hospital & Research Institute
BND Onco Centre
Breach Candy Hospital & Research Centre
Cancer Care Clinic
Cancer Center of America
Cancer Institute
Cancer Research Centre
Caritas Hospital
Center of Blood Disorders
Chittaranjan National Cancer Institute
CHL-CBCC Cancer Center
ClearMedi Radiant Hospital
CMC Medical College
Deenanath Mangeshkar Hospital
Dharamsila Cancer Hospital and Research Center
Doctors And Doctors Plaza
Dr. Manish Nema Clinic & Lab
Dr. Kamakshi Memorial Hospital
Eyesrus Ophthalmic/Eye Hospital
Father Muller Medical College
Fortis Balaji Hospital
Fortis Hospital, Bangalore
Fortis Hospital, Ludhiana
Fortis Memorial Research Institute
G.Kuppuswamy Naidu Memorial Hospital
Ganju Haematology Clinic and Hospital
Gauhati Medical College
Government Medical College
Gujarat Cancer & Research Institute
GVN Hospital
Haemato-Oncology Care Centre (HOCC)
Harshamitra Super Speciality Hospital
HCG Cancer Centre
HCG Cancer Centre, Jaipur
HCG Cancer Centre, Mumbai
HCG Kalyannagar
HCG MSR Centre Of Oncology
HCG Panda Curie Cancer Hospital
HealthCare Global Enterprises Ltd
Hematology & Immunology Cell
Hematology Clinic
Holy Spirit Hospital
Homi Bhabha Cancer Hospital

Hope Cancer Institute
Indira Gandhi Co-Operative Hospital
Indira Gandhi Institute of Medical Sciences (IGIMS)
Indo-American Cancer Institute & Research Centre
Indurkar clinic
Jaslok Hospital and Research Center
Jaypee Hospital
JIPMER
Jupiter Hospital
K R Hospital
Kailash Hospital
Kane Hospital
Kashyap Nursing Home
Kidwai Memorial Institute of Oncology
King George’s Medical College
Kolkata Medical College
Kovai Medical Centre And Hospital
Krishna Hospital
Krishna Institute Medical Sciences Ltd
Kumaran Hospitals Pvt. Ltd
L N Cancer Hospital
LH Hiranandani Hospital
Lokmanya Tilak Municipal General Hospital
Lotus Institute of Hemetology and oncology
Lourdes Hospital
Mahatma Gandhi Medical College & Hospital
Malabar Cancer Center
Manas Hospital
Manavata Cancer Centre
Mangalore Institute of Oncology
Mangalore Institute of Oncology Udupi, Day Care Centre
Manipal Hospital
Manipal Hospital Yeshwanthpur
Manipal Hospital, Comprehensive Cancer Centre
Manipal Hospital, Vijayawada
Marble City Hospital and Research Centre
Max Super Speciality Hospital
Max Super Speciality Hospital, Ghaziabad
Mayom Hospital
Medanta Cancer Institute
Medicity Hospital
MGM’s Medical College & Hospital
Microdiagnostic
Mittal Hospital
MNJ Hospital
Mohan B Agarwal Clinic
Mohan Dai Oswal Cancer Hospital
MS Patel Cancer Center
Mumbai Oncocare Centre

Mumbai Oncocare Centre, Aurangabad
MVR Cancer Center and Research Institute
Naik Super Speciality Hospital
Nair Hospital
Nanavati Super Speciality Hospital
Narayana Hrudayalaya
Narayana Superspeciality Hospital
Narayana Superspeciality Hospital
Narayani Cancer Clinic
National Cancer Institute
Netaji Subhas Chandra Bose Cancer Research Institu
Nil Ratan Sircar Medical College & Hospital (NRSMC&H)
Nizam`s Institute of Medical Sciences
NMR Curie Centre of Oncology
Omega Hospital
Oncowin Cancer Center
P. D. Hinduja Hospital and Medical Research Centre
Paras HMRI Hospital
Park Nursing Home
Patel Hospital
Patna Hematology Clinic
Post Graduate Institute of Medical Education & Research
Pragati Hospital
Prathima Cancer Hospital
Prince Aly Khan Hospital
PSRI Hospital & Research Centre
Punjab Cancer Care & Research Centre
Quality Care Hospital
Qure Hematology and Oncology Centre LLP (Dr Urmish Chudgar)
R.K. Birla Cancer & Res. Center & S.M.Medical Collage
Raheja Hospital
Rajagiri Hospital
Rajendra Institute of Medical Sciences
Rajiv Gandhi Cancer Institute & Research Ctr.
Ram Krishna Cancer Care Clinic
Ravi's American Cancer Care
Regional Cancer Centre
Renova Soumya Cancer Centre
Ruby Hall Clinic
S.C.B. Medical College and Hospital
Safdurjung Hospital
Sahyadri Speciality Hospital
Sakra World Hospital
Sancheti Hospital and Cancer Institute
Sandu Cancer Centre
Sanguine Hematooncology Clinic
Sanjay Gandhi Postgraduate Institute of Medical Sc
Sanjeevani CBCC USA Cancer Hospital

Santokba Durlabhji Memorial Hospital
Saroj Gupta Cancer Center & Research Institute
Saveetha Medical College and Hospital
Shatabdi Hospital
Shyam Hem-Onc Clinic
SIMS Hospital
Sir Ganga Ram Hospital
SMS Medical College and Hospital
Sparsh Hospital and Critical Care Pvt. Ltd.
Sri Aurobindo Cancer Institute of Medical Sciences
Sri Guru Ram Das Institute of Medical Sciences & Research Centre
Sri Ramachandra Medical College & Research Centre
Sri Ramakrishna Institute of Oncology Research
Srinivasan Rajalakshmi Memorial Hospital
St. John's Medical College
Surat Oncology Centre
Sushrut Hospital & Research Centre
Taran OncoCare
Tata Medical Centre
Tata Memorial Hospital
United CIIGMA Hospital
Vadamalayan Hospitals
Vasantha Memorial Cancer Centre
Vasundhara cancer clinic
Vedanta Institute of Medical Sciences
Vizag Haematology Centre
VPS Lakeshore Hospital
VS hospital
Vyas Cancer Care
Vydehi institute of Medical science and Research Center
Yashoda Clinic
Yashoda Hospital
Yashoda Hospital
Yashoda Hospital
Zydus Hospitals Cancer Centre

Jamaica

Cornwall Regional Hospital
Kingston Public Hospital (NPHL)
University Hospital Of The West Indies

Kazakhstan

National Research Oncology Center

Kenya

Aga Khan University Hospital
Coast General Teaching & Referral Hospital
Jaramogi Oginga Odinga Teaching & Referral Hospital
Kenyatta University Teaching Referral And Research Hospital

Moi Teaching & Referral Hospital
Nakuru Level 5 Hospital
The Nairobi Hospital

Kyrgyzstan

National Oncology and Hematology Center

Laos

Mittaphab Hospital

Latvia

Riga East University Hospital

Lithuania

Vilniaus Universiteto Ligoninė Santaros Klinikos

Madagascar

Service d'Oncologie C.H.U – H.J.R.A

Malawi

College of Medicine & Queen Elizabeth Central Hospital
Kamuzu Central Hospital

Mali

Service d'hématologie oncologie médicale

Mauritius

Victoria Hospital Candos

Mexico

Hospital Angeles del Pedregal
Hospital Central de San Luis Potosí “Dr. Ignacio M
Hospital General de Mexico
Hospital General de Occidente, Secretaria de Salud
Hospital Universitario de Nuevo León “Dr. José Ele
Instituto Nacional de Cancerología (INCAN)
Instituto Nacional de Ciencias Médicas y Nutrición
Unidad de Hematología y Transfusión
Unidad de Inmuno-hematología

Moldova

Institute of Oncology

Mongolia

First Central Hospital of Mongolia

Mozambique

Hospital Central de Maputo

Namibia

Private Office Dr. Michael Alison

Nepal

B.P. Koirala Memorial Hospital
Patan Hospital
Sushil Koirala Prakhhar Cancer Hospital

Nicaragua

Hospital Roberto Calderon Gutierrez

Niger

Hôpital National de Niamey

Nigeria

National Hospital, Abuja
Obafemi Awolowo University Teaching Hospitals Comp

Papua New Guinea

Nazarene Health Ministries, INC

Paraguay

Hospital de Clínicas
IPS Central

Peru

Hospital Regional Honorio Delgado
Instituto Nacional de Enfermedades Neoplasicas

Philippines

Asian Hospital and Medical Center
BMSC Medical Imaging Center, O and E Bldg.
Cebu Doctor's Hospital
Chinese General Hospital
Chong Hua Hospital
Lung Center of the Philippines
Makati Medical Center
Medical Arts Bldg. Iloilo Mission Hospital
Medical Arts Bldg., Riverside Medical Center
Medical Center Manila
National Kidney and Transplant Institute
Pediicare Clinic
Perpetual Succor Hospital
Philippine General Hospital
San Pedro Hospital of Davao City
St. Luke's Medical Center
University of Santo Tomas Hospital
Victor R. Potenciano Medical Center
ZAEC Community Medical Center San Jose
Zambales Doctors' Clinics

Republic of Congo

Centre Hospitalier et Universitaire de Brazzaville

Republic of Serbia

University Clinical Center of Serbia

Rwanda

Partners In Health/ Inshuti Mu Buzima
Rwanda Military Hospital

Saint Lucia	Victoria Hospital
Senegal	Hospital Dalal Jamm
Seychelles	Seychelles Hospital
Sierra Leone	Connaught Teaching Hospital, Freetown
Solomon Islands	National Referral Hospital
Sri Lanka	National Cancer Hospital, Maharagama Nawaloka Private Hospital North Colombo Teaching Hospital Ragama Oasis Hospital, Colombo Provincial General Hospital Teaching Hospital, Kandy
Sudan	Port Sudan Oncology Centre
Surinam	University Hospital Paramaribo, AZP
Tajikistan	National Medical Centre of the Republic of Tajikistan “Shifobakhsh”
Tanzania	Kilimanjaro Christian Medical Center Ocean Road Cancer Institute
Togo	Campus Teaching Hospital of Lome
Uganda	Joint Clinical Research Centre Limited Mulago Hospital Uganda Cancer Institute
Uzbekistan	The Republican Specialized Scientific – Practical Medical Center Of Hematology
Vanuatu	Vila Central Hospital
Venezuela	Banco Municipal de Sangre Centro Médico de Caracas
Zambia	University Teaching Hospital Lusaka
Zimbabwe	Parirenyatwa Hospital



Physician Perspective

The invaluable support of UICC members, the National Cancer Council of Mongolia, alongside other key national stakeholders such as the Medical Devices Regulatory Agency and the Pharmaceutical Association, played a crucial role in reaching this significant milestone.

Dr. Dan Milner, Executive Director of ATOM Coalition for UICC



Above: The Max Foundation’s Senior Director of Public Sector Engagement, David Palacios, MD, MHA (right) along with our partner from the American Society for Clinical Pathology (ASCP), Dan Milner, MD (left), and Dr T. Munkhsaikh, Minister of Health of Mongolia.

The Union for International Cancer Control (UICC) on behalf of the Access to Oncology Medicines (ATOM) Coalition in 2024 signed a Memorandum of Understanding with the Ministry of Mongolia, representing an important step towards improving access to quality-assured cancer medicines within the country. The Max Foundation is a founding partner of the ATOM Coalition.

A Message of Hope



Patient Perspective

My message is that regardless of diagnosis, it is possible to live a full and meaningful life. To all those who are fighting this disease, I say that you are not alone and that there is hope.

Sandra from Chile



After overcoming thyroid and breast cancers, Sandra from Chile faced a new challenge: a diagnosis of chronic myeloid leukemia (CML). Since 2015 Sandra has participated in our treatment adherence program, Day by Day, which supports people through monthly phone calls, educational materials, and workshops. Currently 314 people participate in our Day by Day program in four Latin America countries (Chile, Mexico, Paraguay, and the Dominican Republic) with plans underway to launch this program in other regions soon.

CONTACT US

themaxfoundation.org

425 - 778 - 8660

1448 NW Market Street
Suite 500
Seattle, WA 98107

 @themaxfoundation

 @themaxfoundation

 The Max Foundation

 @themaxfoundation.org